Revascularization Strategy for PAD/CLTI: Endovascular, Open, Hybrid, Conduit, and Device Choice

40.1Revascularization strategy begins with limb threat and patient risk

The first strategic decision in PAD/CLTI is not “open versus endovascular”; it is whether revascularization is likely to produce meaningful limb benefit for this patient, in this limb, at this point in the illness. The Global Vascular Guidelines frame that decision around limb threat, anatomic complexity, patient risk, and expected benefit, using WIfI to describe threatened tissue and GLASS to describe arterial anatomy before choosing endovascular, open, hybrid, or non-revascularization care. GVG 2019

For the trainee, WIfI and GLASS should be used as communication tools, not decorative scores. WIfI clarifies whether the clinical problem is ischemic rest pain, tissue loss, infection, or some combination; GLASS clarifies whether the proposed arterial path to the foot is likely to be durable enough to support healing. A low-limb-threat patient with limited expected benefit should not be forced through an elaborate reconstruction simply because a lesion is technically treatable, while a high-limb-threat patient with a plausible target artery deserves a strategy that is more durable than a transient angiographic success. GVG 2019

Patient risk is equally central. The 2024 multisociety PAD guideline frames CLTI revascularization around anatomic pattern, available conduit, comorbidities, and patient preferences. ACC/AHA 2024 A suitable autogenous vein favors bypass when the limb requires a durable reconstruction; absence of usable vein may shift the balance toward an endovascular-first plan, especially when operative risk or recovery burden is high.

Shared decision-making should be practical and explicit. The patient should understand whether the goal is relief of ischemic pain, wound healing, prevention of major amputation, preservation of ambulation, or simply a less invasive attempt before palliation or amputation. In diabetic foot disease, revascularization planning must be integrated with ulcer, infection, and cardiovascular risk management rather than treated as an isolated arterial procedure. AHA Dm Foot 2023 · IWGDF/ESVS 2023

A good revascularization plan also anticipates medical therapy after the procedure. In selected patients after lower-extremity revascularization, low-dose rivaroxaban 2.5 mg twice daily plus low-dose aspirin reduces major cardiovascular and limb events, but the decision must account for bleeding history, intracranial hemorrhage risk, renal function, drug interactions, and timing around the operation or intervention. ACC/AHA PAD 2024 · VOYAGER 2020

40.2Endovascular, open, and hybrid options

Endovascular therapy is best understood as a strategy of lower physiologic stress and repeatability, not as a synonym for inferior care. BASIL-2 randomized CLTI patients requiring infrapopliteal revascularization to vein-bypass-first or best-endovascular-first and found lower major amputation or death with an endovascular-first strategy, with more deaths in the bypass-first arm. BASIL-2 2023 This supports an endovascular-first approach for many infrapopliteal CLTI patients, while reminding the surgeon to examine the trial population, conduit definitions, and local expertise before generalizing.

Open bypass remains the most compelling first strategy when the patient has CLTI, acceptable operative risk, a reconstructible target, and an adequate single-segment great saphenous vein. In BEST-CLI Cohort 1, bypass-first surgery reduced the composite of major adverse limb event or death compared with endovascular-first therapy in patients with an adequate single-segment great saphenous vein. BEST-CLI · 2022 This is the key bedside teaching point: vein availability is not a minor technical detail; it can determine the preferred strategy.

Hybrid care is appropriate when the limb problem cannot be neatly solved by one modality. The Global Vascular Guidelines explicitly include hybrid care within the evidence-based revascularization plan, requiring the surgeon to integrate limb threat, anatomy, patient risk, and expected benefit before committing to a pathway. GVG 2019 The hybrid label should not be used casually; it should describe a coherent plan in which each component solves a specific inflow, outflow, or access problem.

Strategy should not be selected by anatomy alone. The 2024 multisociety PAD guideline emphasizes anatomy, conduit, comorbidities, and patient preference together; suitable vein may favor bypass, while absent vein may favor endovascular-first treatment. ACC/AHA 2024 A patient with severe tissue loss and good vein may reasonably be offered bypass-first therapy; a frail patient without usable conduit may be better served by an endovascular-first attempt even when the anatomy is challenging.

European PAD guidance provides a broad framework for modality choice, revascularization indications, imaging, and post-revascularization therapy, but older European guidance should be treated as legacy context beside newer multisociety PAD and CLTI-specific frameworks. ESC/ESVS 2024 · ESC 2017 In practice, this means the surgeon should align local pathways with current guideline principles while avoiding rigid rules that ignore conduit, patient risk, and limb threat.

40.3Conduit, target, and device choice

Conduit assessment should occur before the strategy conference, not after a decision for bypass has already been made. BEST-CLI Cohort 1 was defined by the presence of an adequate single-segment great saphenous vein, and the bypass-first benefit was shown in that conduit-defined population. BEST-CLI · 2022 The practical lesson is simple: map the vein early, document whether a suitable autogenous conduit exists, and avoid presenting bypass as equivalent across conduit types.

When suitable vein is absent, the decision often moves toward endovascular-first therapy or a more guarded open strategy. The 2024 multisociety PAD guideline supports using available conduit as a key determinant: suitable autogenous vein favors surgical bypass, whereas absence of usable vein may favor an endovascular-first plan. ACC/AHA 2024 Contemporary conduit-comparison evidence also reinforces the clinical concern that prosthetic conduit performs worse than suitable vein in CLTI bypass. Prosthetic Conduits · 2025

Target selection should be tied to expected limb benefit. The Global Vascular Guidelines require that the revascularization plan integrate GLASS anatomy with WIfI limb threat and patient risk; for trainees, that means selecting the arterial path most likely to support wound healing or pain relief rather than simply treating the easiest stenosis. GVG 2019 A technically successful procedure that does not improve the limb’s biologic chance of healing is not a successful strategy.

Device choice in femoropopliteal disease must balance patency benefit against the evolving paclitaxel safety literature. IN.PACT SFA showed substantially higher 12-month primary patency and lower clinically driven target lesion revascularization with paclitaxel-coated balloon angioplasty compared with standard angioplasty. IN.PACT SFA 2015 LEVANT 2 also showed improved 12-month primary patency with a paclitaxel-coated balloon, without significant differences in mortality, amputation, or reintervention at that time point. LEVANT 2 2015

The paclitaxel discussion should be transparent. The 2018 Katsanos meta-analysis reported increased late all-cause mortality after paclitaxel-coated femoropopliteal devices and described a dose-response signal, but later analyses and registry-based randomized evidence have not consistently reproduced the magnitude of that risk. Risk Death Following 2018 SWEDEPAD 1 found no significant difference in ipsilateral major amputation or mortality between paclitaxel-coated and uncoated devices in CLTI patients undergoing infrainguinal endovascular revascularization, and a 2026 randomized-trial meta-analysis found no excess all-cause mortality or major amputation through 5 years. Safety paclitaxel-coated devices 2026 · SWEDEPAD 1 2025

Technical adjuncts should be used for a defined problem, not as ritual. In complex femoropopliteal intervention, flow-controlled anti-embolic technique has been described using proximal antegrade flow arrest to reduce distal embolic risk; this is useful as technical context, but it should not be overinterpreted as broad comparative-effectiveness evidence. Novel technique preventing 2026

40.4Trial evidence and anatomic staging for strategy selection

The modern CLTI strategy discussion is anchored by a tension between BEST-CLI and BASIL-2, and that tension is clinically useful. BASIL-2 2023 · BEST-CLI · 2022 BEST-CLI Cohort 1 supports bypass-first therapy when an adequate single-segment great saphenous vein is present, whereas BASIL-2 supports best-endovascular-first therapy in patients requiring infrapopliteal revascularization. These trials should not be flattened into a single slogan; they define different clinical populations and different starting assumptions.

For the bedside decision, first ask whether the patient resembles the BEST-CLI Cohort 1 patient: CLTI, acceptable operative candidacy, a reconstructible target, and adequate single-segment great saphenous vein. BEST-CLI · 2022 When the answer is yes, bypass-first therapy has randomized support for reducing major adverse limb event or death. When the answer is no, especially when usable vein is absent or patient risk is high, the argument for an endovascular-first plan becomes stronger. ACC/AHA 2024

Next ask whether the patient resembles the BASIL-2 population: CLTI requiring infrapopliteal revascularization, treated in a pragmatic multicenter setting where best-endovascular-first therapy produced lower major amputation or death than vein-bypass-first. BASIL-2 2023 This is particularly important for distal disease, where bypass durability, conduit quality, target quality, and perioperative burden may all influence whether a bypass-first plan truly serves the patient.

Registry data can refine but should not replace randomized evidence. A Medicare-linked VQI analysis comparing bypass with peripheral vascular intervention in below-knee popliteal and infrapopliteal disease found lower 5-year mortality with bypass after matching, while long-term amputation differences were not significant after competing-risk analysis. VQI 2023 This type of evidence is useful for hypothesis generation and real-world context, but it cannot substitute for conduit-stratified randomized trial reasoning.

Anatomic staging should discipline the discussion. The Global Vascular Guidelines require integration of WIfI limb threat, GLASS anatomy, patient risk, and expected limb benefit before selecting the modality. GVG 2019 A high-complexity arterial pathway in a low-risk patient with good vein may justify bypass; the same anatomy in a frail patient without suitable vein may justify endovascular-first treatment or even a non-revascularization pathway when limb benefit is unlikely.

40.5Failure modes, reintervention, and crosslinks to wound and amputation care

Failure begins before the procedure when the wrong endpoint is chosen. In CLTI, the endpoint is not simply crossing a lesion or sewing a bypass; it is achieving enough durable perfusion to support pain relief, wound healing, or limb preservation in a patient whose overall condition makes that goal worthwhile. The Global Vascular Guidelines’ requirement to integrate WIfI, GLASS, patient risk, and expected limb benefit is therefore also a failure-prevention framework. GVG 2019

After bypass, surveillance planning should be realistic about event rates. PREVENT III enrolled 1,404 patients with critical limb ischemia undergoing infrainguinal vein bypass, and although edifoligide did not improve the primary endpoint, the trial remains a canonical real-world CLTI bypass cohort for framing early and 1-year graft-event expectations. Prevent III · 2006 The teaching point is that vein bypass is not a one-time cure; it is a reconstruction that requires structured follow-up and readiness to manage graft-threatening events.

After endovascular therapy, the likely failure mode is restenosis, occlusion, recurrent symptoms, or failure of tissue loss to progress toward healing. Drug-coated femoropopliteal devices improved 12-month patency in IN.PACT SFA and LEVANT 2, but patency benefit must be interpreted alongside patient selection, lesion context, device labeling, and the evolving paclitaxel safety record. IN.PACT SFA 2015 · LEVANT 2 2015 The surgeon should explain that a lower-burden first procedure may still require repeat intervention. Safety paclitaxel-coated devices 2026 · Risk Death Following 2018

Antithrombotic therapy is part of failure prevention. VOYAGER PAD showed that rivaroxaban 2.5 mg twice daily plus aspirin after lower-extremity revascularization reduced acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke, or cardiovascular death at 3 years, with numerically higher TIMI major bleeding that was not statistically significant. VOYAGER 2020 Current PAD guidance supports this regimen in selected post-revascularization patients when bleeding risk is acceptable. ACC/AHA PAD 2024

Reintervention should be triggered by clinical failure, objective graft or lesion concern, or failure of the wound trajectory—not by anxiety alone. For the CLTI patient with tissue loss, reassessment must include the wound, infection status, perfusion adequacy, and whether the chosen target artery is delivering the expected limb benefit. Diabetic foot guidance reinforces that PAD management in patients with foot ulceration must be coordinated with wound and infection care rather than separated into vascular and podiatric silos. IWGDF/ESVS 2023 · SVS Dm Foot 2016

Amputation planning is not a declaration of defeat when revascularization cannot deliver meaningful benefit. A non-revascularization pathway is explicitly part of the CLTI decision framework when patient risk, anatomy, conduit, limb threat, and expected benefit do not support intervention. The senior surgeon’s responsibility is to identify that point honestly, preserve function when possible, and keep wound care, rehabilitation, and cardiovascular risk management active even when limb salvage is no longer the right endpoint. AHA Dm Foot 2023 · GVG 2019